Comparative Pharmacology
Head-to-head clinical analysis: NORTREL 1 35 21 versus WOLFINA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NORTREL 1 35 21 versus WOLFINA.
NORTREL 1/35-21 vs WOLFINA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination of ethinyl estradiol (estrogen) and norethindrone (progestin) suppresses gonadotropin (FSH and LH) release from the pituitary, inhibiting ovulation, altering cervical mucus to impede sperm penetration, and inducing endometrial changes that reduce implantation likelihood.
Not specified in available data; likely unapproved or investigational drug.
One tablet orally once daily for 21 days, followed by 7 days off, then repeat.
Initial: 50 mg orally twice daily. Titrate to 100 mg twice daily after 2 weeks based on tolerability.
None Documented
None Documented
Norethindrone: 5-14 hours; Ethinyl estradiol: 17-24 hours. Steady-state achieved after 10 days.
Terminal elimination half-life is 12-18 hours in healthy adults; prolonged to 24-36 hours in renal impairment (CrCl <30 mL/min), requiring dose adjustment.
Renal 50-60% as metabolites, fecal 40-50% as conjugates, <1% unchanged
Primarily renal (70% unchanged), with 20% biliary/fecal and 10% metabolic degradation.
Category C
Category C
Oral Contraceptive
Oral Contraceptive